Carbidopa

Type: Keyphrase
Name: Carbidopa
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

New treatment for Parkinson’s disease

Dr. Anne-Louise Lafontaine, neurologist and Director of the Movement Disorders Clinic at The Neuro.This fall, the Montreal Neurological Institute and Hospital (The Neuro, at McGill University and the McGill University Health Centre) expects to introduce ... [Published Hospital News - Sep 17 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 2 reports

Deep Brain Stimulation Devices Market for Parkinson’s Disease to be Worth $9.4 Billion by 2019

Press ReleasesDeep Brain Stimulation Devices Market for Parkinson’s Disease to be Worth $9.4 Billion by 2019Transparency Market Research includes new market research report "Deep Brain Stimulation Devices Market" to its huge collection of research re ... [Published Scoop Asia - Sep 11 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 2 reports

NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson's Disease

., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a high-dose ... [Published Wall Street Select - Sep 03 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Teva Recalls ‘Super Potent’ Parkinson’s Disease Medication

Voluntary action applies to entire U.S.Teva Pharmaceutical Industries has recalled one lot of its generic Parkinson’s disease (PD) combination medication carbidopa/levodopa because it may contain too much of an active pharmaceutical ingredient.The company ... [Published PT Community - Aug 27 2014]
First reported May 16 2014 - Updated May 16 2014 - 1 reports

Deep Brain Stimulation Devices Market: Global Industry Analysis, Size,...

Transparency Market Research published a new report "Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse full report: A rise in ageing population has been found ... [Published PRWeb - May 16 2014]

Quotes

"ND0612H is being developed for severe stage Parkinson's disease patients who are refractory to oral levodopa and have only limited remaining treatment options such as continuous intra-duodenal LD/CD gel infusion and Deep Brain Stimulation. Both treatments require highly invasive surgical intervention and are associated with serious complications. Many patients, therefore, are either deterred or prevented from using them" said Oded S Lieberman
Transparency Market Research published a new report "Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store...

More Content

All (10) | News (6) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New treatment for Parkinson’s disease [Published Hospital News - Sep 17 2014]
Deep Brain Stimulation Devices Market for Parki... [Published Scoop Asia - Sep 11 2014]
Deep Brain Stimulation Devices Market for Parki... [Published MyNewsDesk - Sep 11 2014]
NeuroDerm Announces Start of Phase 2a Study of ... [Published Wall Street Select - Sep 03 2014]
NeuroDerm Announces Start of Phase 2a Study of ... [Published PR Newswire: Policy & Public Interest - Sep 03 2014]
Teva Recalls ‘Super Potent’ Parkinson’s Disease... [Published PT Community - Aug 27 2014]
Deep Brain Stimulation Devices Market: Global I... [Published PRWeb - May 16 2014]
CARBIDOPA Tablet [Amerigen Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
CARBIDOPA Tablet [Amerigen Pharmaceuticals, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 11 2014]
NeuroDerm Announces Enrollment in a Second Phas... [Published PR Newswire: Health - Mar 11 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
NeuroDerm Announces Start of Phase 2a Study of ... [Published PR Newswire: Policy & Public Interest - Sep 03 2014]
REHOVOT, Israel, September 3, 2014 /PRNewswire/ --NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled ...
CARBIDOPA Tablet [Amerigen Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Updated Date: Mar 20, 2014 EST ...
CARBIDOPA Tablet [Amerigen Pharmaceuticals, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 11 2014]
Updated Date: Mar 11, 2014 EST ...
NeuroDerm Announces Enrollment in a Second Phas... [Published PR Newswire: Health - Mar 11 2014]
REHOVOT, Israel, March 11, 2014 /PRNewswire/ --NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.